Protocol Ledger

NCT05317416 · Phase III · ACTIVE NOT RECRUITING

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Interventional Phase III clinical trial protocol NCT05317416 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-25 Enrollment: 854 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05317416
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)854 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05317416
Protocol FieldVerified Registry Value
NCT IdentifierNCT05317416
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment854 participants (ACTUAL)
Registered Start Date2022-03-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI